Using Iambic Therapeutics’ AI/HTE platform, researchers at the company have engineered a next-generation HER2 inhibitor with superb selectivity for HER2, as well as broad mutant coverage and brain penetrance. The compound, IAM-1363, binds to HER2 in a type II DFG-out conformation, which represents the first reported type II HER2 tyrosine kinase inhibitor.
Beijing Avistone Pharmaceuticals Biotechnology Co. Ltd. has disclosed spiro/bridged ring compounds acting as HER2 (erbB2) (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla mutant]) inhibitors reported to be useful for the treatment of atherosclerosis, cancer and pulmonary fibrosis.
A recent patent from Korea University Research & Business Foundation Sejong Campus describes quinazoline-benzimidazole derivatives acting as microtubule destabilizers (tubulin polymerization inhibitors) and HER2 inhibitors reported to be useful for the treatment of cancer.
Hanyang University and Korea Institute of Science and Technology have disclosed HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer.
Iambic Therapeutics Inc. has described HER2 (erbB2) and HER2 (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla]) mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Zhejiang Wenda Pharma Technology Ltd. has identified HER2 (erbB2) and its (exon 20 insertion [Ex20Ins], (Ala775_Gly776insTyrValMetAla)) mutant inhibitors reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed HER2 (erbB2) and/or HER2 (erbB2) mutant inhibitors reported to be useful for the treatment of cancer.
